Division of Cardiology, Department of Medicine, University of California-Irvine, Irvine, CA, United States.
Department of Microbiology, School of Basic Medical Sciences, Harbin Medical University, Harbin, China.
Front Endocrinol (Lausanne). 2022 May 3;13:799521. doi: 10.3389/fendo.2022.799521. eCollection 2022.
Coronavirus disease 2019 or COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a significant threat to the health of human beings. While wearing mask, maintaining social distance and performing self-quarantine can reduce virus spreading passively, vaccination actively enhances immune defense against COVID-19. However, mutations of SARS-CoV-2 and presence of asymptomatic carriers frustrate the effort of completely conquering COVID-19. A strategy that can reduce the susceptibility and thus prevent COVID-19 while blocking viral invasion and pathogenesis independent of viral antigen stability is highly desirable. In the pathogenesis of COVID-19, endocrine disorders have been implicated. Correspondingly, many hormones have been identified to possess therapeutic potential of treating COVID-19, such as estrogen, melatonin, corticosteroids, thyroid hormone and oxytocin. Among them, oxytocin has the potential of both treatment and prevention of COVID-19. This is based on oxytocin promotion of immune-metabolic homeostasis, suppression of inflammation and pre-existing comorbidities, acceleration of damage repair, and reduction of individuals' susceptibility to pathogen infection. Oxytocin may specifically inactivate SARS-COV-2 spike protein and block viral entry into cells angiotensin-converting enzyme 2 by suppressing serine protease and increasing interferon levels and number of T-lymphocytes. In addition, oxytocin can promote parasympathetic outflow and the secretion of body fluids that could dilute and even inactivate SARS-CoV-2 on the surface of cornea, oral cavity and gastrointestinal tract. What we need to do now is clinical trials. Such trials should fully balance the advantages and disadvantages of oxytocin application, consider the time- and dose-dependency of oxytocin effects, optimize the dosage form and administration approach, combine oxytocin with inhibitors of SARS-CoV-2 replication, apply specific passive immunization, and timely utilize efficient vaccines. Meanwhile, blocking COVID-19 transmission chain and developing other efficient anti-SARS-CoV-2 drugs are also important. In addition, relative to the complex issues with drug applications over a long term, oxytocin can be mobilized through many physiological stimuli, and thus used as a general prevention measure. In this review, we explore the potential of oxytocin for treatment and prevention of COVID-19 and perhaps other similar pathogens.
新型冠状病毒病 2019 或 COVID-19 是由严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)引起的,它已成为人类健康的重大威胁。虽然戴口罩、保持社交距离和自我隔离可以被动地减少病毒传播,但疫苗接种则主动增强了对 COVID-19 的免疫防御。然而,SARS-CoV-2 的突变和无症状携带者的存在,使完全征服 COVID-19 的努力受挫。因此,一种既能降低易感性,从而预防 COVID-19,又能独立于病毒抗原稳定性阻断病毒入侵和发病机制的策略,是非常需要的。在 COVID-19 的发病机制中,内分泌失调已经被证实。相应地,已经发现许多激素具有治疗 COVID-19 的潜力,如雌激素、褪黑素、皮质类固醇、甲状腺激素和催产素。其中,催产素具有预防和治疗 COVID-19 的双重潜力。这是基于催产素促进免疫代谢平衡、抑制炎症和已有的合并症、加速损伤修复,以及降低个体对病原体感染的易感性。催产素可能通过抑制丝氨酸蛋白酶、增加干扰素水平和 T 淋巴细胞数量来特异性地使 SARS-CoV-2 刺突蛋白失活并阻断病毒进入细胞的血管紧张素转换酶 2。此外,催产素可以促进副交感神经传出和体液分泌,从而稀释甚至灭活角膜、口腔和胃肠道表面的 SARS-CoV-2。我们现在需要做的是临床试验。这些试验应充分权衡催产素应用的利弊,考虑催产素作用的时间和剂量依赖性,优化剂型和给药途径,将催产素与 SARS-CoV-2 复制抑制剂结合使用,应用特定的被动免疫,并及时利用高效疫苗。同时,阻断 COVID-19 的传播链和开发其他有效的抗 SARS-CoV-2 药物也很重要。此外,与长期应用药物的复杂问题相比,催产素可以通过许多生理刺激来调动,因此可以作为一般的预防措施。在本综述中,我们探讨了催产素治疗和预防 COVID-19 甚至其他类似病原体的潜力。